Skip to main content
SpringerLink
Log in

Aromatase and its inhibitors in breast cancer treatment — overview and perspective

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Estrogen has an important role in stimulating the growth of breast carcinomas. Inhibition of estrogen production is therefore a logical treatment strategy. A number of selective inhibitors have been developed against aromatase, a cytochrome P-450 enzyme which catalyzes the rate limiting step in the biosynthesis of estrogens. The mechanisms of the aromatase reaction, current knowledge of the enzyme, and regulation of its expression are discussed as the basis for inhibitor development. Two classes of aromatase inhibitors, steroidal and non-steroidal compounds, are now coming into use. Among the steroid substrate analogues, 4-hydroxyandrostenedione (4-OHA) has been shown to be effective in breast cancer patients with advanced disease and was recently approved for treatment in the United Kingdom. Several different classes of compounds which act as aromatase inhibitors are currently in clinical trials and should provide breast cancer patients with a number of treatment options. Among these are highly potent and selective non-steroidal inhibitors which have recently been found to suppress plasma and urinary estrogens over 95% in breast cancer patients. The potency of these newer aromatase inhibitors provides the opportunity to determine whether complete suppression of estrogen production and action will result in enhanced tumor regression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McGuire WL: An update on estrogen and progesterone receptors in prognosis for primary and advanced breast Cancer.In: Iacobelli Set al (eds) Hormones and Cancer, Vol. 15. Raven Press, New York, 1980, pp 337–344.

    Google Scholar 

  2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15, 1992.

    Google Scholar 

  3. Santen RJ, Worgul TJ, Lipton A, Harvey HA, Boucher A, Samojlik E, Wells SA: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma: correlation of clinical and hormonal responses. Ann Intern Med 96:94–101, 1982.

    Google Scholar 

  4. Goss PE, Coombes RL, Powles TJ, Dowsett M, Brodie AMH: Treatment of advanced postmenopausal breast cancer with aromatase inhibitor, 4-hydroxyandrostenedione — Phase 2 report. Cancer Res 46:4823–4826, 1986.

    Google Scholar 

  5. Thompson EA Jr, Siiteri PK: Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 249:5364–5372, 1974.

    Google Scholar 

  6. Morato T, Hayano M, Dorfman RI and Axelrod LR: The intermediate steps in the biosynthesis of estrogens from androgens. Biochem Biophys Res Commun 6: 334–338, 1961.

    Google Scholar 

  7. Meyer AS: Conversion of 19-hydroxy-4-androstene-3,17-dione to estrone by endocrine tissue. Biochim Biophys Acta 17:441–442, 1955.

    Google Scholar 

  8. Zhou D, Korzekwa KR, Poulos T, Chen S: A sitedirected mutagenesis study of human placental aromatase. J Biol Chem 262:4421–4426, 1992.

    Google Scholar 

  9. Graham-Lorence S, Khalil MW, Lorence MC, Mendelson CR, Simpson ER: Structure function relationships of human aromatase cytochrome P-450 using molecular modeling and site-directed mutagenesis. J Biol Chem 266:11030–11946, 1991.

    Google Scholar 

  10. Oh SS, Robinson CH: Mechanism of placental aromatase: A new active site model. J Steroid Biochem Mol Biol 44:389–397, 1993.

    Google Scholar 

  11. Cole PA and Robinson CH: Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 33:2933–2942, 1990.

    Google Scholar 

  12. Akhtar M, Calder MR, Corina DL, Wright JN: Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. Biochem J 201:569–580, 1982.

    Google Scholar 

  13. Cole PA, Robinson CH: A peroxide model reaction for placental aromatase. J Am Chem Soc 110:1284–1285, 1988.

    Google Scholar 

  14. Stevenson DE, Wright JN, Akhtar M: Synthesis of 19-functionalised derivatives of 16α-hydroxytestosterone: Mechanistic studies on oestriol biosynthesis. J Chem Soc Chem Commun 1078–1080, 1985.

  15. Stevenson DE, Wright JN, Akhtar M: Mechanistic consideration of P-450 dependent enzymatic reactions: Studies on oestriol biosynthesis. J Chem Soc, Perkin Trans I:2043–2052, 1988.

    Google Scholar 

  16. Morato T, Raab K, Brodie HJ, Hayano M, Dorfman RI: The mechanism of estrogen biosynthesis. J Am Chem Soc 84:3764–3765, 1962.

    Google Scholar 

  17. Schwarzel WC, Kruggel W and Brodie HJ: Studies on the mechanism of estrogen biosynthesis. VII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92:866–880, 1973.

    Google Scholar 

  18. Brodie AMH, Schwarzel WC, Brodie HJ: Studies on the mechanism of estrogen biosynthesis in the rat ovary — 1. J Steroid Biochem 7:787–793, 1976.

    Google Scholar 

  19. Brodie AMJ, Wu JT, Marsh DA, Brodie HJ: Aromatase inhibitors, III. Studies on the antifertility effects of 4-acetoxy-4-androstene-3,17-dione. Biol Reprod 18: 365–370, 1978.

    Google Scholar 

  20. Marsh DA, Brodie HJ, Garrett WM, Tsai-Morris CH, Brodie AMH: Aromatase inhibitors — synthesis and biological activity of androstenedione derivatives. J Med Chem 28:788, 1985.

    Google Scholar 

  21. Brodie AMH, Garrett W, Hendrickson JM, Marsh DA, Brodie HJ: The effect of 1,4,6-androstatriene-3,17-dione (ATD) on DMBA-induced mammary tumors in the rat and its mechanism of actionin vivo. Biochemical Pharmacol 31:2017–2023, 1982.

    Google Scholar 

  22. Samojlik E, Santen RJ, Wells SA: Adrenal suppression with aminoglutethimide, II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J Clin Endocrinol Metab 45:480–487, 1977.

    Google Scholar 

  23. Covey DF, Hood WF: Enzyme generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity. Endocrinology 108:1597–1599, 1981.

    Google Scholar 

  24. Brodie AMH, Hendrickson JR, Tsai-Morris CH, Garrett WM, Marcotte PA, Robinson CH: Inactivation of aromatase in vitro by 4-OHA and 4-acetoxyandrostenedione and sustained effects in vivo. Steroids 38:693–702, 1981.

    Google Scholar 

  25. Sjoerdsma A: Suicide inhibitors as potential drugs. Clin Pharm Therap 30:3–22, 1981.

    Google Scholar 

  26. Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC: Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 49: 1306–1312, 1989.

    Google Scholar 

  27. Brueggemeier RW, Li PK, Snider CE, Darby MV, Katlic NE: 7α-substituted androstenediones as effectivein vitro andin vivo inhibitors of aromatase. Steroids 50:163–178, 1987.

    Google Scholar 

  28. Brueggemeier RW, Li PK, Chen HH, Moh PP, Katlic NE: Biochemical pharmacology of new 7-substituted androstenediones as inhibitor of aromatase. J Steroid Biochem 37:379–385, 1990.

    Google Scholar 

  29. Dowsett M, MacNeil F, Mehta A, Newton C, Haynes B, Jones A, Jarman M, Lonning, PE, Powles TJ, Coombes RC: Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (‘pyridoglutethimide’) in postmenopausal breast cancer patients. Br J Cancer 64:887–894, 1991.

    Google Scholar 

  30. Stanek J, Alder A, Bellus D, Bhatnagar AS, Hausler A, Schieweck K: Synthesis and aromatase inhibitory activity of novel 1-(4-aminophenyl)-3-azabicyclo-[3.1.0]hexane-and [3.1.1]heptane-2,4-diones. J Med Chem 34:1329–1334, 1991.

    Google Scholar 

  31. Van Wauwe JP, Janssen PAJ: Is there a case for P-450 inhibitors in cancer treatment? J Med Chem 32:2231–2239, 1989.

    Google Scholar 

  32. Laughton C, Zvelebil MJJM, Neidle S: A detailed molecular model for human aromatase. J Steroid Biochem Mol Biol 44:399–407, 1993.

    Google Scholar 

  33. Wouters W, DeCoster R, Beerens D, Doolaege R, Gruwez JA, Van Camp K, Van Der Pas H, Van Herendael B: Potency and selectivity of the aromatase inhibitor R 76 713. A study in human ovarian, adipose stromal, testicular and adrenal cells. J Steroid Biochem 36:57–65, 1990.

    Google Scholar 

  34. Bhatnagar AS, Hausler A, Trunet P, Muller Ph, Lang M, Bowman P: Inhibitors of estrogen biosynthesis: CGS 16949A and CGS 20267, preclinical and clinical endocrine effects. Symp. Aromatase Inhibition — Past, Present and Future, 15th Int. Cancer Congr., Hamburg, 1990, p 13.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, School of Medicine, University of Maryland, 21201, Baltimore, MD, USA

    Angela M. H. Brodie

  2. Department of Internal Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA

    Richard J. Santen

Authors
  1. Angela M. H. Brodie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard J. Santen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brodie, A.M.H., Santen, R.J. Aromatase and its inhibitors in breast cancer treatment — overview and perspective. Breast Cancer Res Tr 30, 1–6 (1994). https://doi.org/10.1007/BF00682736

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00682736

Key words

Search

Navigation